meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Conditions:   Peritoneal Dialysis Complication;   End Stage Kidney Disease;   Sodium-glucose Co-transporter-2 Inhibitors;   Kidney Dysfunction;   Residual Kidney Function Intervention:   Drug: Empagliflozin 25 MG Sponsor:   University Health Network, Toronto Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials